The Community Resource in Targeted Therapies
Driving Knowledge. Empowering Change. Optimizing Outcomes.
ONCAlert | Upfront Therapy for mRCC

Next Steps Beyond the MONARCH 1 Trial in Breast Cancer

Maura N. Dickler, MD
Published Online: 8:27 PM, Fri June 10, 2016
Maura N. Dickler, MD, Memorial Sloan Kettering Cancer Center, discusses next steps with abemaciclib following the results of the single-arm MONARCH 1 trial, which examined the efficacy of the CDK4/6 inhibitor in heavily pretreated patients with refractory, hormone-receptor–positive, HER2-negative advanced breast cancer.

Copyright © TargetedOnc 2018 Intellisphere, LLC. All Rights Reserved.